PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
DRAFT — Version 3 — For Client Review — December 16, 2023 C&H Matter Number: 1018-00009
PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
TRANSMITTAL MEMORANDUM
December 16, 2023
TO: Marcus Whitfield, VP, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
FROM: Leonard Cross, Responsible Partner, Calderwood & Harkness LLP Sylvia Hartwell, Billing Partner, Calderwood & Harkness LLP Garrett Simmons, Lead Associate, Calderwood & Harkness LLP Leila Nazari, Working Associate, Calderwood & Harkness LLP
RE: Draft Formal Protest — Version 3 — Penterra Pharmaceuticals Corp. — TY 2017–2020 (IRS Exam Team LB&I-NE-TP-2022-00641)
This memorandum transmits the enclosed Draft Formal Protest (Version 3) for your review and comment. This version incorporates all revisions from Version 1 (December 5, 2023) and Version 2 (December 12, 2023), reflecting comments from Leonard Cross and Sylvia Hartwell received on December 8 and December 14, 2023, respectively. The protest has been prepared for filing with the Internal Revenue Service in response to the 30-Day Letter dated November 8, 2023, and the Notice of Proposed Adjustment dated October 12, 2023, and requests transfer of the case to the IRS Office of Appeals pursuant to Revenue Procedure 2015-41.
We respectfully request that Penterra provide approval or remaining comments no later than December 19, 2023, to allow adequate time for finalization, execution of the perjury statement, and filing on or before the extended deadline of December 22, 2023.
Please direct all comments to Garrett Simmons (gsimmons@calderwoodharkness.com; 215-555-4820) and Leila Nazari (lnazari@calderwoodharkness.com; 215-555-4837), with copies to Leonard Cross and Sylvia Hartwell.
PRIVILEGED AND CONFIDENTIAL — ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
FORMAL PROTEST
Filed on Behalf of: PENTERRA PHARMACEUTICALS CORP. EIN: 22-3741856 2200 Independence Boulevard Princeton Junction, New Jersey 08550
Tax Years at Issue: 2017, 2018, 2019, 2020
Filed in Response to: 30-Day Letter Dated November 8, 2023 Notice of Proposed Adjustment ("NOPA") Dated October 12, 2023
IRS Examination Team: LB&I-NE-TP-2022-00641 LB&I Northeast Transfer Pricing Practice
Examining Agents: Supervisory Revenue Agent Gerald Meskill (Team Manager) Lead Revenue Agent Patricia Dunleavy
IRS Office of Chief Counsel: Attorney-Advisor Franklin Rosario Senior Counsel Donna Hirabayashi
IRS Economist: Dr. Alan Washburne
Authorized Representatives: Leonard Cross (Responsible Partner) Sylvia Hartwell (Billing Partner) Garrett Simmons (Lead Associate) Leila Nazari (Working Associate) Calderwood & Harkness LLP 1735 Market Street, Suite 3100 Philadelphia, Pennsylvania 19103 (Lead Office)
Also: 600 Lexington Avenue New York, New York 10022
Power of Attorney: IRS Form 2848 Filed June 8, 2022
Request for Transfer to IRS Office of Appeals Pursuant to Rev. Proc. 2015-41
DRAFT — Version 3 — For Client Review — December 16, 2023
Right-click to update Table of Contents
I. INTRODUCTION AND SUMMARY OF PROTEST
Penterra Pharmaceuticals Corp. ("PPC" or "Taxpayer"), a Delaware corporation publicly traded on the Nasdaq Global Select Market (ticker symbol: PPCA), hereby files this Formal Protest pursuant to Revenue Procedure 2015-41, §§ 2.01–2.05, and respectfully protests the proposed adjustments set forth in the Notice of Proposed Adjustment ("NOPA") dated October 12, 2023, issued by the Internal Revenue Service Large Business & International Division, Northeast Transfer Pricing Practice, Exam Team LB&I-NE-TP-2022-00641. PPC received a 30-Day Letter dated November 8, 2023, accompanying the NOPA. PPC timely requests that its case be transferred to the IRS Office of Appeals for de novo consideration.
The original 30-day period for filing this Protest would have expired on December 8, 2023. By mutual agreement between PPC's authorized representatives and the examination team, the deadline was extended to December 22, 2023. This Protest is being filed within the extended deadline.
The NOPA proposes a net aggregate adjustment of $380,400,000 to PPC's federal income tax returns (Forms 1120) for Tax Years 2017, 2018, 2019, and 2020 (collectively, the "Exam Years"). The proposed adjustments comprise three components:
(a) Cost-Sharing Arrangement Adjustments: $235,010,000 — The IRS proposes to increase the cost-sharing percentages paid by PPC's Irish subsidiary, Penterra Biopharma International DAC ("PBI"), under a qualified cost-sharing arrangement ("CSA") by 8 to 12 percentage points per year, thereby reallocating income from PBI to PPC.
(b) Royalty Rate Adjustments: $188,040,000 — The IRS proposes to increase the royalty rate on a legacy intangible property license from 4.5% to 11.0% of net sales, asserting that PPC's arm's-length rate is inadequate based on comparables selected by the IRS economist.
(c) Correlative Offset: ($42,650,000) — The examination team allowed a partial correlative offset to avoid certain double-counting between the CSA and royalty adjustments.
In addition, the IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty of approximately $15,977,000, computed as 20% of the underpayment of tax attributable to the proposed net § 482 adjustment of $380,400,000. The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h).
PPC contends that each of these proposed adjustments is without merit and should be eliminated in its entirety. PPC's transfer pricing methodologies for the CSA and the legacy IP license fully satisfy the arm's-length standard under Internal Revenue Code ("IRC" or "Code") § 482 and the applicable Treasury Regulations, including Treas. Reg. §§ 1.482-1, 1.482-4, and 1.482-7.
With respect to the CSA cost-sharing adjustments, PPC's cost-sharing percentages for the Exam Years (ranging from 38.2% to 42.7%) are based on reasonably anticipated benefits calculated pursuant to Treas. Reg. § 1.482-7(e) using contemporaneously developed revenue projections that reflect arm's-length allocations of intangible development costs. The IRS's proposed percentages (ranging from 48.2% to 53.7%) lack analytical support and produce results that are inconsistent with the arm's-length standard by attributing to PBI a disproportionately small residual return that is incommensurate with PBI's substantive functions, assets, and risk-bearing capacity.
With respect to the royalty rate adjustments, PPC's 4.5% royalty rate on legacy IP licensed to PBI is virtually at the median (4.4%) of the arm's-length range (3.1% to 6.8%) established by 14 comparable uncontrolled pharmaceutical license transactions identified by PPC's independent economic advisors. The IRS's proposed 11.0% rate is based on non-comparable transactions that are materially distinguishable from the controlled transaction on critical comparability dimensions.
With respect to the IRS's underlying challenge to PBI's economic substance, PBI is a bona fide Irish entity with 185 employees, independent decision-making authority over 68 non-Americas country markets, €47.2 million in cumulative regulatory expenditures during the Exam Years, an independent board of directors that held 42 meetings in Dublin during the relevant period, and comprehensive Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions relating to PPC's pharmaceutical IP in the non-Americas territory. PBI is not a conduit or shell entity, and the IRS's economic substance challenge is factually unfounded.
Finally, PPC maintains that the proposed IRC § 6662(e) penalty should be fully abated. PPC maintained contemporaneous transfer pricing documentation for all four Exam Years in compliance with IRC § 6662(e)(3)(B) and Treas. Reg. § 1.6662-6, establishing a rebuttable presumption of reasonable cause and good faith. PPC's transfer pricing positions were developed with the assistance of qualified professionals and are well within the arm's-length range. There is no basis for imposing any penalty.
II. IDENTIFICATION OF TAXPAYER AND TAX PERIODS
A. Taxpayer Information
The Taxpayer filing this Formal Protest is Penterra Pharmaceuticals Corp. The following information identifies the Taxpayer for purposes of this proceeding:
PPC is a specialty pharmaceutical and biotechnology company engaged in the research, development, manufacture, and commercialization of innovative therapeutics in the areas of oncology, immunology, and rare-disease therapeutics. PPC is a publicly traded company whose shares are listed on the Nasdaq Global Select Market under the ticker symbol PPCA. PPC was not a participant in the IRS Compliance Assurance Process ("CAP") for any of the tax years at issue.
B. Tax Periods Under Examination
The tax periods under examination and the subject of this Protest are:
(a) Tax Year 2017: January 1, 2017 through December 31, 2017
(b) Tax Year 2018: January 1, 2018 through December 31, 2018
(c) Tax Year 2019: January 1, 2019 through December 31, 2019
(d) Tax Year 2020: January 1, 2020 through December 31, 2020
PPC notes that the Tax Cuts and Jobs Act of 2017 ("TCJA"), Pub. L. No. 115-97, reduced the federal corporate income tax rate from 35% to 21% effective January 1, 2018. Accordingly, TY 2017 is subject to the pre-TCJA rate of 35%, while TY 2018, TY 2019, and TY 2020 are subject to the post-TCJA rate of 21%. This rate change is relevant to the computation of the proposed penalty and to the interaction between the proposed § 482 adjustments and the TCJA's international provisions, including the Global Intangible Low-Taxed Income ("GILTI") provisions under IRC § 951A and the Base Erosion and Anti-Abuse Tax ("BEAT") provisions under IRC § 59A, as discussed in Section IX below.
C. Officers and Key Personnel
The following officers and key personnel of PPC are identified for purposes of this Protest:
PPC's federal income tax returns for the Exam Years were prepared by Crestfield & Associates LLP, an independent public accounting firm, under the direction of Martin Ogilvy, CPA, Engagement Partner, and Susan Lam, CPA, Transfer Pricing Partner. Crestfield & Associates LLP maintains its principal office at 1200 Avenue of the Americas, New York, New York 10036. Crestfield also prepared PPC's contemporaneous transfer pricing documentation for all four Exam Years, as discussed further in Section III.E and Section VII below.
III. STATEMENT OF FACTS
A. PPC's Corporate Structure and Business Operations
Penterra Pharmaceuticals Corp. is a specialty pharmaceutical and biotechnology company headquartered in Princeton Junction, New Jersey. PPC is principally engaged in the research, development, manufacture, and commercialization of innovative therapeutics targeting oncology, immunology, and rare-disease indications. PPC's product portfolio includes several commercially significant branded pharmaceuticals and biologics that are marketed and sold on a global basis.
PPC's key products and their respective global and non-Americas net sales for the fiscal year ended December 31, 2020, are as follows:
Veritaxol is PPC's flagship oncology product, a biologic approved for multiple indications including metastatic non-small cell lung cancer, renal cell carcinoma, and urothelial carcinoma. Veritaxol accounted for approximately 45.7% of PPC's consolidated global net sales in FY 2020 and has been PPC's principal growth driver during the Exam Years. Imvara is an immunology product approved for moderate-to-severe rheumatoid arthritis and psoriatic arthritis, while Cerulon is an orphan drug indicated for the treatment of a rare lysosomal storage disorder.
PPC's corporate ownership structure for the entities relevant to this Protest is as follows:
(a) Penterra Pharmaceuticals Corp. (Delaware, U.S.) — the U.S. parent and publicly traded entity;
(b) Penterra Holdings Luxembourg S.à r.l. ("PHL") — a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg, and registered with the Luxembourg Register of Commerce and Companies (Registre de Commerce et des Sociétés, "RCS") under Number B 168452. PHL is 100% owned by PPC and is treated as a disregarded entity for U.S. federal income tax purposes;
(c) Penterra Biopharma International DAC ("PBI") — a Designated Activity Company organized under Irish law, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland, and its Irish Tax Reference Number 3218764T. PBI is 100% owned by PHL (and thus, by reason of PHL's disregarded status, is treated as a controlled foreign corporation ("CFC") directly owned by PPC for U.S. federal income tax purposes). PBI serves as the IP-holding company and principal for the commercialization of PPC's pharmaceutical products outside the Americas;
(d) Penterra Manufacturing Ireland Ltd. ("PMI") — a private limited company organized under Irish law, with its registered office at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, and its Companies Registration Office ("CRO") Number 512347. PMI is a wholly owned subsidiary of PBI and operates as a contract manufacturer of oncology and immunology biologics for distribution in non-Americas markets. PMI operates under a cost-plus arrangement with PBI, receiving a markup of 8% over its fully loaded manufacturing costs. PMI employs approximately 620 employees at its manufacturing facility in Ringaskiddy, Co. Cork.
A corporate structure chart illustrating the foregoing ownership chain is attached hereto as Exhibit A.
B. Establishment of Penterra Biopharma International DAC (PBI)
PBI was incorporated on March 15, 2012, as a Designated Activity Company under Irish law. PBI was established to serve as the IP-holding company and commercial principal for the marketing, distribution, and sale of PPC's pharmaceutical products in territories outside the Americas. For purposes of the relevant intercompany agreements, "Americas" is defined as North America, Central America, South America, and the Caribbean. PBI thus holds rights relating to the Europe, Middle East, and Africa ("EMEA") and Asia-Pacific ("APAC") regions.
PBI's Managing Director is Aidan Naughton, who has been based in Dublin, Ireland, since PBI's incorporation. Mr. Naughton has primary executive responsibility for PBI's non-Americas commercial operations, reporting to PPC's Chief Commercial Officer for global coordination purposes while maintaining independent authority over pricing, market entry, distribution partner selection, and regulatory strategy in PBI's territory.
At the time of its establishment in 2012, PBI employed 52 individuals. PBI's workforce grew steadily over the ensuing years as the non-Americas business expanded, reaching 185 employees by the end of fiscal year 2020. PBI's employees include professionals engaged in regulatory affairs, medical affairs, commercial strategy and marketing, supply-chain management, market access and health economics, pharmacovigilance and drug safety, legal and IP management, and financial management.
PBI's functional profile is substantial and reflects genuine operational capacity and decision-making authority. PBI's principal functions include, but are not limited to:
(a) Regulatory affairs, including the preparation, submission, and management of regulatory filings with the European Medicines Agency ("EMA"), the UK Medicines and Healthcare products Regulatory Agency ("MHRA"), Japan's Pharmaceuticals and Medical Devices Agency ("PMDA"), and other national regulatory authorities across PBI's 68 country markets;
(b) Medical affairs, including oversight of non-Americas clinical programs, post-marketing studies, key opinion leader engagement, and medical education initiatives;
(c) Commercial strategy, including brand planning, marketing campaign development, pricing decisions, and promotional activities across PBI's territory;
(d) Supply-chain management, including coordination with PMI (PBI's contract manufacturer in Ringaskiddy, Co. Cork) and management of third-party logistics providers for distribution across 68 markets;
(e) Selection and management of distribution partners, including negotiation of distribution agreements, assessment of distributor performance, and management of direct-to-market sales operations in key territories;
(f) Independent pricing decisions across all 68 country markets, including negotiations with governmental reimbursement authorities in regulated markets; and
(g) Market entry decisions, including evaluation of commercial opportunity, competitive landscape, and regulatory pathway for new market launches.
PBI maintains approximately 18,000 square feet of dedicated office space at Sandyford Business Park, Dublin, Ireland. This space houses PBI's management team, functional departments, and supporting infrastructure.
PBI's board of directors held a total of 42 formal board meetings during the Exam Years (TY 2017–2020), all of which were held in Dublin, Ireland. These meetings consisted of regular quarterly meetings as well as special sessions convened to address significant business decisions. Board meeting minutes document substantive deliberations and decisions regarding pricing strategy, market entry in new territories, regulatory submissions, capital expenditures, distribution partner arrangements, and other matters within PBI's business scope.
PBI's cumulative expenditures on regulatory submissions across non-Americas territories during the Exam Years totaled approximately €47.2 million. These expenditures reflect PBI's active involvement in securing and maintaining regulatory approvals for PPC's pharmaceutical products in diverse jurisdictions with distinct regulatory requirements.
PBI's financial performance for FY 2020 demonstrates the scale and substance of its operations: PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI maintains independent banking relationships with Glenmore Bank Ireland plc and exercises independent control over its financial operations, including treasury management, accounts receivable and payable, and capital allocation decisions.
PBI engages Thornbury & Keogh, Chartered Tax Advisors, 22 Fitzwilliam Square, Dublin 2, D02 YH68 (Lead Partner: Ciarán Thornbury), as its Irish tax advisors. PBI's effective Irish tax rate on trading income is 12.5%, consistent with Ireland's standard corporate tax rate. Beginning with fiscal year 2016, PBI has claimed benefits under Ireland's Knowledge Development box ("KDB") regime at an effective rate of 6.25% on qualifying income derived from qualifying intellectual property assets.
C. The Cost-Sharing Arrangement (CSA)
Effective July 1, 2012, PPC and PBI entered into a Cost-Sharing Arrangement (the "CSA") structured as a qualified cost-sharing arrangement within the meaning of Treas. Reg. § 1.482-7. Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical intangible property portfolio in territories outside the Americas (i.e., EMEA and APAC), while PPC retained the right to develop and exploit the same IP portfolio within the Americas.
In connection with the execution of the CSA, PBI made a platform contribution transaction ("PCT") payment to PPC in the amount of $312,000,000, paid as a lump sum on July 1, 2012. The PCT payment represented arm's-length compensation for PBI's buy-in to the pre-existing intangible property resources, capabilities, and rights that PPC made available to PBI under the CSA. At the time of the PCT, PPC's pre-existing IP consisted primarily of clinical-stage and approved oncology compounds, including early formulations of what would become Veritaxol, as well as certain immunology assets in earlier stages of development.
Under the ongoing cost-sharing provisions of the CSA, PBI's share of annual qualified research and development costs is determined in proportion to PBI's share of the reasonably anticipated benefits expected to be derived by each controlled participant from the intangible development activities. The reasonably anticipated benefit shares are calculated based on projected revenue splits between the Americas territory (PPC's territory) and the non-Americas territory (PBI's territory), in accordance with Treas. Reg. § 1.482-7(e).
PBI's cost-sharing percentages and the corresponding dollar amounts of cost-sharing payments for each of the Exam Years are set forth in the following table:
The progressive increase in PBI's cost-sharing percentage from 38.2% in 2017 to 42.7% in 2020 reflects the increasing proportion of total product revenues generated outside the Americas during this period, consistent with the growth trajectory of PPC's key products in international markets. Revenue projections underlying the cost-sharing percentages were contemporaneously developed using PPC's internal financial forecasting models and were reviewed and validated by PPC's transfer pricing advisors at Crestfield & Associates LLP.
A summary of the CSA's key terms and cost-sharing methodology is attached hereto as Exhibit B.
D. The Legacy IP License Agreement
Separate and apart from the CSA, PPC and PBI entered into a License Agreement (the "Legacy IP License") under which PBI licenses certain legacy pharmaceutical compounds from PPC. The legacy compounds consist of pre-2012 vintage products whose intangible property rights were not contributed to or covered by the CSA. These are older products with established market positions but declining revenue trajectories, consistent with the typical pharmaceutical product lifecycle.
Under the Legacy IP License, PBI pays PPC a royalty of 4.5% of net sales of the legacy compounds in the non-Americas territory. The royalty rate was established at the inception of the license based on a comparable uncontrolled transaction analysis conducted by Crestfield & Associates LLP and was supported by PPC's contemporaneous transfer pricing documentation.
The legacy compound non-Americas net sales and corresponding royalties paid by PBI to PPC for each of the Exam Years are as follows:
As reflected in the foregoing table, non-Americas net sales of the legacy compounds declined steadily over the Exam Years, falling from $814.6 million in 2017 to $624.1 million in 2020 — a decline of approximately 23.4% over the four-year period. This decline is consistent with the typical lifecycle trajectory of mature pharmaceutical products, which experience diminishing revenues as patents expire, generics enter the market, and prescribing patterns shift toward newer therapies.
E. Contemporaneous Transfer Pricing Documentation
PPC maintained contemporaneous transfer pricing documentation for all four Exam Years (TY 2017, TY 2018, TY 2019, and TY 2020). The documentation was prepared by Crestfield & Associates LLP under the direction of Susan Lam, CPA, Transfer Pricing Partner, who has extensive experience in pharmaceutical transfer pricing and has served as PPC's transfer pricing advisor since 2011.
The contemporaneous documentation was prepared in compliance with the standards set forth in IRC § 6662(e)(3)(B) and Treas. Reg. § 1.6662-6, and was in existence at the time each respective return was filed. The documentation addressed, among other matters:
(a) The CSA cost-sharing methodology under Treas. Reg. § 1.482-7, including the computation of reasonably anticipated benefit shares, the composition and allocation of the qualified R&D cost pool, and the validation of cost-sharing percentages;
(b) The royalty rate methodology under Treas. Reg. § 1.482-4, including the identification and analysis of comparable uncontrolled transactions and the application of the CUT method to establish the arm's-length royalty rate for the Legacy IP License; and
(c) The overall transfer pricing system applied to PPC's controlled transactions with PBI and PMI, including functional analysis, economic analysis, and method selection.
The contemporaneous documentation constitutes the foundation of PPC's penalty protection defense, as detailed in Section VII below.
F. The IRS Examination
The IRS examination of PPC's Forms 1120 for TY 2017–2020 commenced on May 16, 2022, when PPC received a Letter 2205-A, Examination Notification. The examination was conducted by the Large Business & International ("LB&I") Division, Northeast Transfer Pricing Practice, under Exam Team ID LB&I-NE-TP-2022-00641. Supervisory Revenue Agent Gerald Meskill served as Team Manager, and Lead Revenue Agent Patricia Dunleavy directed the day-to-day examination activities. The examination team was supported by Attorney-Advisor Franklin Rosario and Senior Counsel Donna Hirabayashi of the IRS Office of Chief Counsel, as well as by IRS Economist Dr. Alan Washburne.
Over the course of the examination, the IRS issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023. PPC cooperated fully with the examination and produced extensive documentation responsive to all IDRs. The categories of documents and information produced include, without limitation:
(a) Corporate organizational charts for PPC and all related entities;
(b) The CSA agreement (executed July 1, 2012) and all amendments thereto;
(c) The Legacy IP License agreement;
(d) Contemporaneous transfer pricing documentation for TY 2017–2020;
(e) PCT valuation workpapers prepared in connection with the July 2012 buy-in;
(f) R&D cost pool composition data and allocation workpapers for each Exam Year;
(g) PBI financial statements (audited) and Irish tax returns for TY 2017–2020;
(h) PBI headcount and personnel data, including employee rosters, job descriptions, and organizational charts;
(i) PBI board of directors meeting minutes (42 meetings during 2017–2020);
(j) PMI contract manufacturing agreement with PBI;
(k) Product revenue data disaggregated by territory, product, and sales channel;
(l) PBI office lease documentation for Sandyford Business Park, Dublin;
(m) PBI regulatory expenditure records and regulatory submission histories;
(n) Distribution agreements between PBI and third-party distribution partners;
(o) PBI banking records with Glenmore Bank Ireland plc;
(p) Comparable license agreements identified in the CUT analysis;
(q) PBI's Irish Knowledge Development box filings;
(r) Intercompany pricing decision memoranda;
(s) Forms 5471 (Information Return of U.S. Persons With Respect to Certain Foreign Corporations) for PBI for all Exam Years;
(t) Capital expenditure records for PBI and PMI; and
(u) Supplemental documentation responsive to follow-up IDRs.
PPC's representatives participated in multiple conferences with the examination team, including an opening conference, periodic status conferences, and a closing conference. PPC provided access to key personnel for interviews, including 12 PBI employees interviewed in Dublin during August and September 2022.
G. Notice of Proposed Adjustment (October 12, 2023)
On October 12, 2023, the examination team issued the NOPA proposing a net aggregate adjustment of $380,400,000 to PPC's taxable income for TY 2017–2020. The 30-Day Letter accompanying the NOPA was issued on November 8, 2023.
The NOPA proposes three categories of adjustments — CSA cost-sharing ratio adjustments, legacy IP royalty rate adjustments, and a correlative offset — as well as a substantial valuation misstatement penalty under IRC § 6662(e). The specific amounts by issue and year are detailed in Section IV below.
IV. SUMMARY OF PROPOSED ADJUSTMENTS AND AMOUNTS IN DISPUTE
A. CSA Cost-Sharing Ratio Adjustments ($235,010,000)
The IRS proposes to increase PBI's cost-sharing percentage under the CSA by 8 to 12 percentage points in each Exam Year. The IRS asserts that PPC's projections of reasonably anticipated benefits understated the value attributable to the U.S.-based research and development activities and correspondingly overstated the non-Americas territory's share of anticipated benefits. As a result, the IRS contends that PBI should have borne a higher proportion of the annual qualified R&D costs and that the differential represents additional income properly allocable to PPC under IRC § 482.
The year-by-year detail of the proposed CSA adjustments is as follows:
PPC disputes the entire $235,010,000 CSA adjustment for the reasons set forth in Section VI.A below.
B. Legacy IP Royalty Rate Adjustments ($188,040,000)
The IRS proposes to increase the royalty rate under the Legacy IP License from 4.5% to 11.0% of non-Americas net sales, representing a differential of 6.5 percentage points. The IRS's proposed rate is based on comparable uncontrolled transaction ("CUT") data selected by IRS Economist Dr. Alan Washburne from third-party pharmaceutical licensing agreements that the IRS asserts are comparable to the PPC-PBI Legacy IP License.
The year-by-year detail of the proposed royalty rate adjustments is as follows:
PPC disputes the entire $188,040,000 royalty rate adjustment for the reasons set forth in Section VI.B below.
C. Correlative Offset (($42,650,000))
The examination team allowed a correlative offset of ($42,650,000) to avoid double-counting between the CSA cost-sharing adjustments and the royalty rate adjustments. PPC acknowledges that the examination team's recognition of this offset is appropriate in principle; however, as discussed in Section VI.F below, PPC contends that the $42,650,000 offset does not fully correct the potential double-counting that would arise if both the CSA and royalty adjustments were sustained.
D. Net Proposed Adjustment
The net proposed adjustment across all four Exam Years is calculated as follows:
E. Proposed Penalty
The IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty of approximately $15,977,000. The penalty is computed as follows:
Net § 482 Adjustment: $380,400,000 Applicable Corporate Tax Rate: 21% Underpayment of Tax: $380,400,000 × 21% = $79,884,000 Penalty Rate: 20% Penalty Amount: $79,884,000 × 20% = $15,976,800 (approximately $15,977,000)
PPC notes that this computation applies the 21% post-TCJA rate uniformly to the entire adjustment, though TY 2017 was subject to the 35% rate. The penalty computation may require adjustment depending on the allocation of the net adjustment among tax years.
The IRS reserved but did not assert the 40% gross valuation misstatement penalty under IRC § 6662(h). PPC contends that the 20% penalty under § 6662(e) is likewise inapplicable, as discussed in Section VII below.
F. IRS's Economic Substance Challenge
In addition to the specific numerical adjustments described above, the IRS asserted in the NOPA that PBI lacks sufficient economic substance to justify its role as IP owner and CSA participant. The IRS's economic substance challenge contends that key DEMPE functions — specifically, the Development, Enhancement, Maintenance, Protection, and Exploitation of PPC's pharmaceutical intangibles — remained in the United States under the control and direction of PPC, rather than being genuinely performed by PBI in Ireland. The IRS asserts that PBI's role is that of a passive recipient of income rather than an entity that earns returns commensurate with the functions it performs, the assets it uses, and the risks it assumes.
This economic substance position underlies and supports both the CSA cost-sharing adjustments and the royalty rate adjustments. PPC's detailed refutation of this position is set forth in Section VI.C below.
G. IRS's PCT Position
The IRS further asserted that the $312,000,000 PCT payment made by PBI to PPC on July 1, 2012, undervalued the pre-existing intellectual property contributed to the CSA by approximately $540 million. The IRS valued the PCT at $852,000,000 using an income method with a weighted average cost of capital ("WACC") of 7.2% and revenue projections that differed from those used by PPC's advisors at the time of the transaction.
Although the 2012 tax year is outside the Exam Years (TY 2017–2020), the IRS used this assertion to support its position that the ongoing CSA cost-sharing ratios and royalty rates for the Exam Years should be recharacterized to account for the alleged undervaluation of the PCT. PPC's response to this position is set forth in Section VI.A.3 below.
V. STATEMENT OF LAW
A. IRC § 482 — Allocation of Income Among Commonly Controlled Entities
Section 482 of the Internal Revenue Code authorizes the Secretary of the Treasury, in any case of two or more organizations, trades, or businesses owned or controlled directly or indirectly by the same interests, to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses.
The fundamental principle underlying § 482 is the arm's-length standard: controlled transactions must produce results consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. See Treas. Reg. § 1.482-1(b)(1). The arm's-length standard is the benchmark against which the pricing and other terms of intercompany transactions are evaluated.
The IRS bears the burden of demonstrating that PPC's controlled transactions with PBI do not reflect arm's-length results before any reallocation under § 482 is warranted. Moreover, any allocation made by the IRS must itself be consistent with the arm's-length standard; the IRS does not have unfettered discretion to assign income between related parties without regard to economic reality. See Harborview Corporation, Inc. v. Commissioner, 154 T.C. 138 (2020), aff'd in part, rev'd in part, No. 21-1151 (8th Cir. Aug. 2, 2022).
B. Treas. Reg. § 1.482-1(d) — Arm's-Length Standard and Best Method Rule
Treasury Regulation § 1.482-1(c) sets forth the "best method rule," which requires that the arm's-length result of a controlled transaction be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. The reliability of a method depends on two primary factors:
(a) Comparability: The degree of comparability between the controlled transaction (or the taxpayer) and any uncontrolled comparables, taking into account all factors that could affect prices or profits in arm's-length dealings. The principal comparability factors include functional analysis (functions performed, assets used, and risks assumed), contractual terms, economic conditions and market conditions, and property or services transferred. See Treas. Reg. § 1.482-1(d)(1)–(3).
(b) Quality of Data and Assumptions: The completeness and accuracy of the data used and the reliability of the assumptions underlying the analysis. See Treas. Reg. § 1.482-1(c)(2)(ii).
The regulations establish no hierarchy among transfer pricing methods; the selection of the best method depends on the facts and circumstances of each case. See Treas. Reg. § 1.482-1(c)(1). This is a critical principle in the present dispute because the IRS's proposed adjustments rest on the assertion that its selected methods and comparables are superior to PPC's — a contention that PPC vigorously disputes, as demonstrated in Section VI below.
C. Treas. Reg. § 1.482-7 — Qualified Cost-Sharing Arrangements
Treasury Regulation § 1.482-7 governs the tax treatment of qualified cost-sharing arrangements. A CSA is an arrangement under which two or more controlled participants agree to share the costs of developing intangibles in proportion to their shares of the reasonably anticipated benefits from the intangible development activity. See Treas. Reg. § 1.482-7(a).
The principal requirements for a qualified CSA under the regulations include:
(a) Eligibility of Controlled Participants: Each controlled participant must reasonably expect to derive benefits from the intangible development activity. See Treas. Reg. § 1.482-7(c)(1).
(b) Scope of Intangible Development Activity: The CSA must define the intangible development activity that is the subject of cost sharing. See Treas. Reg. § 1.482-7(d).
(c) Reasonably Anticipated Benefits: Each participant's cost-sharing percentage must be determined based on that participant's share of the reasonably anticipated benefits from the intangible development activity. Reasonably anticipated benefits are measured by the benefits each participant reasonably anticipates at the time of cost determination, using the most reliable projections available. See Treas. Reg. § 1.482-7(e).
(d) Platform Contribution Transactions: When a controlled participant makes pre-existing resources, capabilities, or rights available to the CSA, the other participants must make arm's-length payments (platform contribution transaction payments) to compensate for such contributions. See Treas. Reg. § 1.482-7(g).
The regulations prescribe several methods for determining PCT payments, including the income method, the acquisition price method, the market capitalization method, the residual profit split method, the comparable uncontrolled transaction method, and unspecified methods. See Treas. Reg. § 1.482-7(g)(4)–(9). The selection of the most appropriate method is governed by the best method rule of Treas. Reg. § 1.482-1(c).
The PPC-PBI CSA satisfies each of these regulatory requirements, as demonstrated by the facts set forth in Section III.C above and the arguments set forth in Section VI.A below.
D. Treas. Reg. § 1.482-4 — Methods for Intangible Property
Treasury Regulation § 1.482-4 prescribes methods for determining the arm's-length consideration for controlled transfers of intangible property. The principal method relevant to this Protest is the comparable uncontrolled transaction ("CUT") method, which evaluates whether the amount charged in a controlled transfer of intangible property was arm's-length by reference to the amount charged in a comparable uncontrolled transaction. See Treas. Reg. § 1.482-4(c).
The comparability factors specific to intangible property transactions include:
(a) The nature and type of the intangible property (e.g., patent, trademark, know-how);
(b) The rights transferred, including geographic scope, field-of-use limitations, and exclusivity;
(c) The stage of development of the intangible property at the time of transfer;
(d) The uniqueness of the intangible and the expected profit attributable thereto;
(e) The expected future benefits from the intangible, including projected revenue streams;
(f) The duration of the rights transferred; and
(g) Any other factors that could affect prices in arm's-length dealings.
See Treas. Reg. § 1.482-4(c)(2)(iii)(B). The CUT method is applicable to the Legacy IP License and is the method employed by both PPC and the IRS to evaluate the arm's-length royalty rate — though the parties reach markedly different conclusions, as discussed in Section VI.B below.
Other methods applicable to intangible property transactions include the comparable profits method ("CPM") and the profit split method, set forth in Treas. Reg. §§ 1.482-5 and 1.482-6, respectively.
E. Economic Substance Doctrine and DEMPE Framework
The economic substance doctrine, codified at IRC § 7701(o), requires that a transaction have both (i) objective economic substance, meaning that the transaction changes the taxpayer's economic position in a meaningful way apart from federal income tax effects, and (ii) a subjective business purpose, meaning that the taxpayer entered into the transaction for a substantial non-tax business purpose. Both prongs must be satisfied.
In the transfer pricing context, the economic substance inquiry intersects with the concept of DEMPE functions as articulated in the Organisation for Economic Co-operation and Development ("OECD") Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations ("OECD Guidelines"). Chapter VI of the OECD Guidelines (Special Considerations for Intangibles), as revised in 2017 and 2022, establishes that the entity performing and controlling the Development, Enhancement, Maintenance, Protection, and Exploitation ("DEMPE") functions with respect to intangible property is entitled to the returns attributable to those functions. See OECD Guidelines, Chapter VI, paras. 6.47–6.71.
Chapter VIII of the OECD Guidelines (Cost Contribution Arrangements) provides guidance on the structuring and evaluation of cost contribution arrangements, including the determination of expected benefits and the allocation of contributions. See OECD Guidelines, Chapter VIII, paras. 8.1–8.52.
While the OECD Guidelines are not binding authority in U.S. transfer pricing disputes, they are recognized by the IRS and the U.S. Tax Court as persuasive authority. See, e.g., Harborview Corporation, Inc. v. Commissioner, 154 T.C. at 186 n.26 (citing OECD Guidelines); Hollowell & Co. v. Commissioner, 148 T.C. 108, 165 (2017) (referencing OECD guidance on cost-sharing arrangements).
PBI's DEMPE functions, as documented in Section III.B above and Section VI.C below, fully support PBI's entitlement to the returns it earned during the Exam Years.
F. IRC § 367(d) — Transfer of Intangibles to Foreign Corporations
IRC § 367(d) provides that if a United States person transfers intangible property to a foreign corporation in an exchange described in § 351 or § 361, the transferor must include in gross income an amount equal to an annual payment that would be required under IRC § 482 as if the intangible property had been licensed to the foreign corporation. The interplay between § 367(d) and § 482 is relevant in the CSA context because the IRS has occasionally sought to recharacterize CSA buy-in payments as § 367(d) outbound transfers.
As discussed in Section VI.E below, the PPC-PBI CSA is a properly structured qualified cost-sharing arrangement under Treas. Reg. § 1.482-7, and PBI's rights under the CSA arise from its ongoing cost-sharing contributions and its PCT payment — not from a § 367(d) outbound transfer of intangibles from PPC to a foreign corporation.
G. IRC § 6662(e) — Substantial Valuation Misstatement Penalty
IRC § 6662(e) imposes a 20% penalty on any underpayment of tax attributable to a substantial valuation misstatement in connection with transactions between commonly controlled entities under § 482. A substantial valuation misstatement exists where the net § 482 transfer pricing adjustment for a taxable year exceeds the lesser of $5,000,000 or 10% of the taxpayer's gross receipts for the year. See IRC § 6662(e)(1)(B).
The penalty is computed on the underpayment of tax attributable to the § 482 adjustment, not on the adjustment itself.
H. IRC § 6662(e)(3)(B) — Penalty Protection / Reasonable Cause Defense
IRC § 6662(e)(3)(B) provides that the substantial valuation misstatement penalty shall not apply to any portion of an underpayment if the taxpayer establishes that there was reasonable cause for the underpayment and that the taxpayer acted in good faith with respect to such portion.
A taxpayer is deemed to have established reasonable cause if the taxpayer maintains contemporaneous documentation that meets the requirements specified in the regulations and provides such documentation to the IRS within 30 days of a request. See IRC § 6662(e)(3)(B)(i)–(ii). Treasury Regulation § 1.6662-6 specifies the documentation requirements, including that the documentation must be in existence at the time the return is filed and must describe, among other things, the method selected, the reasons for selecting that method, and the economic analysis supporting the taxpayer's transfer pricing positions.
As discussed in Section VII below, PPC's contemporaneous transfer pricing documentation meets all applicable requirements, and PPC is entitled to full abatement of the proposed penalty.
I. Relevant Case Law